Press Releases :: ProMIS Neurosciences, Inc. (PMN)

Nov 20, 2023 7:00am EST

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

Nov 14, 2023 4:30pm EST

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 08, 2023 7:00am EDT

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 06, 2023 12:18pm EDT

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023 4:12pm EDT

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023 5:33pm EDT

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023 7:00am EDT

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

Jul 14, 2023 7:45am EDT

ProMIS Announces Completion of Continuance

Jul 10, 2023 7:55am EDT

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jun 30, 2023 8:00am EDT

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved